Actinogen trial: Alzheimer's drug slows decline by 30pc in over-75s
Australian biotech Actinogen says its daily pill Emestedastat slowed Alzheimer's progression by 30 per cent in patients over 75, though the phase 2 trial missed statistical significance across all 247 participants. The company now plans a 700-patient study starting mid-2027 and hopes for a market launch by 2030.
- Original source: news24.com.au.
- The source published it on Nov 18, 2026 at 7:04 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Actinogen's experimental pill Emestedastat slowed Alzheimer's progression by 30 per cent in trial participants older than the median age of 75, the Australian biotech revealed on Thursday. That group made up half of the 247 patients enrolled across Australia and the US. The phase 2 trial did not record a statistically significant benefit when the whole group was measured together.
Participants took the daily pill, branded Xanamem, for 36 weeks, and all had mild to moderate disease. The drug works by blocking production of the stress hormone cortisol in key areas of the brain. According to Actinogen, most patients reported few side effects across the treatment period.
Chief executive Steven Gourlay pointed to a $10.8m research and development tax incentive rebate from the federal government as a boost to the company's cash position during the trial. He said the rebate encourages firms like his to keep research in Australia. It has been good for Australian jobs and science, he added, and for answering questions like whether a drug that controls cortisol works in Alzheimer's disease.
The next trial is expected to enroll 700 patients and begin in mid-2027, with Actinogen aiming to reach the market in 2030. Gourlay said a successful result would put the company in a position to mass produce the drug, pending approval from the Therapeutic Goods Administration. He also welcomed a future Pharmaceutical Benefits Scheme listing after further trials and pricing assessments, saying he would build economic data showing the drug prevents nursing home admissions, improves quality of life and cuts system costs.
The results landed the same day Dementia Australia published No Time to Lose: A United Call for National Dementia Reform, renewing its push for federal action. Dementia is the leading cause of death among Australians, and Dementia Australia counts 446,500 people living with the condition nationally, a figure it expects to pass one million by 2065.
Dementia Australia CEO Professor Tanya Buchanan said the National Dementia Action Plan is an important foundation but needs sustained investment. The organisation is advocating for a national brain health and dementia risk reduction campaign, clear diagnostic pathways, a network of dementia care navigators, more accessible respite and a review of residential aged care funding. Buchanan called on the Australian Government to work with the sector and people with lived experience on those priorities through the 2027-28 budget.
TopicsActinogen · Emestedastat · Xanamem · Steven Gourlay · Dementia Australia · Tanya Buchanan · Therapeutic Goods Administration · Pharmaceutical Benefits Scheme
Source: news24.com.au
Written by AI from verified reporting.
More stories
- Health & science ibtimes.co.uk 3 sources 0 viewsFDA clears Sanofi's Infilbray, first Gaucher drug that reaches the brain
- Health & science finance.yahoo.com 6 sources 1 viewFDA clears Regeneron's Livsayis, a gMG shot dosed four times a year
- Health & science cardiovascularbusiness.com 1 viewFDA moves to yank liquid statin FloLipid off US shelves
- Health & science cnbc.com Caught by @bayu.lestari45 1 viewFDA's Case Against Cheap-Drug Sellers Rests on a Rival CEO Turned Informant

